3SE2

Human poly(ADP-ribose) polymerase 14 (PARP14/ARTD8) - catalytic domain in complex with 6(5H)-phenanthridinone

Summary for 3SE2

• Entry DOI: 10.2210/pdb3se2/pdb
• Related: 3GOY 3SMI
• Descriptor: Poly [ADP-ribose] polymerase 14, phenanthridin-6(5H)-one, GLYCEROL, ... (7 entities in total)
• Functional Keywords: diphtheria toxin like fold, transferase, nad+, adp-ribosylation, structural genomics, structural genomics consortium, sgc
• Biological source: Homo sapiens (human)
• Cellular location: Nucleus : Q460N5
• Total number of polymer chains: 4
• Total formula weight: 89750.62

Authors

Karlberg, T.,Schutz, P.,Arrowsmith, C.H.,Berglund, H.,Bountra, C.,Collins, R.,Edwards, A.M.,Ekblad, T.,Graslund, S.,Kouznetsova, E.,Moche, M.,Nordlund, P.,Nyman, T.,Thorsell, A.G.,Tresaugues, L.,Weigelt, J.,Siponen, M.I.,Schuler, H.,Structural Genomics Consortium (SGC) (deposition date: 2011-06-10, release date: 2011-07-06, Last modification date: 2024-11-20)

Primary citation

Wahlberg, E.,Karlberg, T.,Kouznetsova, E.,Markova, N.,Macchiarulo, A.,Thorsell, A.G.,Pol, E.,Frostell, A.,Ekblad, T.,Oncu, D.,Kull, B.,Robertson, G.M.,Pellicciari, R.,Schuler, H.,Weigelt, J.
Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors.
Nat.Biotechnol., 30:283-288, 2012

PubMed Abstract: Inhibitors of poly-ADP-ribose polymerase (PARP) family proteins are currently in clinical trials as cancer therapeutics, yet the specificity of many of these compounds is unknown. Here we evaluated a series of 185 small-molecule inhibitors, including research reagents and compounds being tested clinically, for the ability to bind to the catalytic domains of 13 of the 17 human PARP family members including the tankyrases, TNKS1 and TNKS2. Many of the best-known inhibitors, including TIQ-A, 6(5H)-phenanthridinone, olaparib, ABT-888 and rucaparib, bound to several PARP family members, suggesting that these molecules lack specificity and have promiscuous inhibitory activity. We also determined X-ray crystal structures for five TNKS2 ligand complexes and four PARP14 ligand complexes. In addition to showing that the majority of PARP inhibitors bind multiple targets, these results provide insight into the design of new inhibitors.

PubMed: 22343925
DOI: 10.1038/nbt.2121

Experimental method

X-RAY DIFFRACTION (2.3 Å)